Both CGON and IDYA operate in oncology, one of biotechnology's most capital-intensive and catalyst-driven corners, yet the two names are moving in very different directions. CGON, or CG Oncology, is a late-stage developer of a bladder-sparing therapy for bladder cancer. IDYA, or IDEAYA Biosciences, is a precision-medicine oncology company targeting genetically defined patient populations. This stock comparison is relevant for growth-oriented investors and traders who track clinical milestones, relative performance, and market positioning among pre-commercial biotech companies with substantial cash balances. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CGON (CG Oncology) is a late-stage clinical biopharmaceutical company developing cretostimogene, an investigational bladder-sparing immunotherapy for non-muscle invasive bladder cancer (NMIBC). The company went public in early 2024 and has since been one of the stronger performers in the development-stage biotech group.
Recent market activity has favored the stock, with shares approaching record highs in recent weeks. Sentiment has been supported by pivotal Phase 3 data showing that its lead candidate reduced the risk of recurrence by roughly 68%, results published in a peer-reviewed medical journal. Management has guided toward several near-term milestones, including additional Phase 3 data readouts and a planned regulatory submission for an initial indication. The company reported roughly $984 million in cash and marketable securities, which it states funds operations into 2029. Analysts broadly rate the stock a Strong Buy, with price targets comfortably above recent trading levels. From what I see, the consistency in upward price action stands out here.
IDYA (IDEAYA Biosciences) is a precision-medicine oncology company advancing targeted small-molecule therapies for patients selected using molecular diagnostics. Its pipeline spans programs such as darovasertib for uveal melanoma and additional assets in MTAP-deletion and DLL3-expressing cancers, alongside research collaborations with larger pharmaceutical partners.
Recent performance has been more subdued. Shares have declined over the past several weeks and are down year-to-date, even as the company retains a cash position of roughly $1.2 billion with a stated runway into 2030. The company also reorganized its research-and-development leadership, concentrating responsibility in a single senior executive. A recent quarter reflected a sharp year-over-year revenue decline, largely because prior periods included milestone-related payments, while net losses widened. Analysts maintain a generally constructive outlook, but near-term price action has lagged the broader market, reflecting investor focus on upcoming clinical and regulatory catalysts. I’m watching this closely as the broader pipeline could provide more options over time.
The two companies diverge most clearly on market positioning and momentum. CGON is concentrated on a single, late-stage bladder cancer program with a near-term regulatory catalyst and a comparatively narrower risk profile, and its share price has responded with sustained strength. IDYA is more diversified across multiple precision-oncology assets, which can spread binary clinical risk but also introduces more execution variables and a longer path to any single approval.
On financial footing, both are pre-commercial and unprofitable, yet each holds a multi-year cash runway that reduces near-term dilution risk. In terms of recent relative performance, CGON has been climbing toward highs while IDYA has been consolidating lower, a contrast that shapes current market sentiment even though both carry analyst ratings that skew bullish.
When comparing names like these, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get a quick read on recent trend consistency across the sector. It helps surface patterns that might otherwise take hours to review manually, especially when evaluating relative strength between two clinical-stage biotechs.
Weighing trend consistency, price stability, catalyst proximity, and relative positioning, Tickeron's AI would currently favor CGON over IDYA. CGON exhibits stronger and more consistent upward momentum, backed by recently published positive data and a visible regulatory milestone, whereas IDYA faces a choppier technical picture despite its broader pipeline. This assessment reflects observable factors and is expressed in probabilistic terms rather than as a definitive forecast.
Tickeron’s Trending AI Robots page highlights a curated selection of AI trading bots chosen for their suitability to current market conditions. Tickeron offers hundreds of AI trading bots that trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of tracked securities. Rather than presenting every available bot, the platform surfaces the strongest performers most aligned with the present environment. Whether you are evaluating the relative momentum of CGON versus IDYA or scanning the broader market, exploring Trending AI Robots can help you identify data-driven strategies that match your trading approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Oscillator for IDYA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 28 of the 33 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 63 cases where IDYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IDYA just turned positive on November 11, 2026. Looking at past instances where IDYA's MACD turned positive, the stock continued to rise in 40 of 48 cases over the following month. The odds of a continued upward trend are 83%.
Following a +4.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in 217 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDYA as a result. In 83 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
The Aroon Indicator for IDYA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.514) is normal, around the industry mean (3.498). P/E Ratio (-16.271) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (14.409) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. IDYA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 80 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.
Industry Biotechnology